See the DrugPatentWatch profile for bicalutamide
Why did bicalutamide fall out of favor for prostate cancer in many cases?
Bicalutamide is an androgen receptor blocker used to treat prostate cancer, often in combination with other hormonal therapies. It has not disappeared, but many clinicians use other regimens more often because they can be more effective or better supported by long-term outcome data in specific disease settings.
What changed in prostate cancer treatment—more effective options?
Over time, treatment for prostate cancer expanded beyond older anti-androgen strategies. Clinicians increasingly favor therapies that more reliably lower androgen signaling or reduce deaths, depending on the stage:
- In advanced disease, standard care often includes medical castration plus an anti-androgen, with newer or better-studied combinations used more commonly.
- In some settings, clinicians have shifted toward drugs and strategies with stronger evidence for survival benefit than bicalutamide-based regimens.
Does bicalutamide still have a role today?
Yes. Bicalutamide can still be used, especially when its specific profile fits a patient’s needs and when an appropriate guideline or clinical context supports it. It may be chosen when clinicians want an androgen receptor blocker without immediately using (or alongside) other hormonal approaches. Its use also depends on disease stage, prior treatments, and patient-specific factors.
Are side effects a reason it’s not as widely used?
Side effects can influence prescribing. Bicalutamide can cause hormone-related effects (for example, breast tenderness or enlargement) and other adverse effects that may make other options preferable for many patients. In practice, the choice of therapy often balances cancer control with tolerability.
Is “not used now” because of guidance for specific stages?
Often, yes. The biggest drivers are how clinicians match therapies to the stage and goal of treatment (curative-intent vs disease control vs symptom management). If a regimen is less aligned with current stage-specific recommendations or less effective in that scenario, it becomes less common even if it still works.
When might a clinician still consider it?
Bicalutamide may be considered when:
- An androgen receptor blockade approach is appropriate for that patient’s disease stage and treatment history.
- The prescriber is aiming for a hormonal strategy where bicalutamide has a known place (depending on local standards and available alternatives).
- The patient’s situation favors its risk/benefit profile compared with other androgen-targeting drugs.
What to check if you’re comparing it to other anti-androgens?
If you’re trying to understand why bicalutamide is less used in your setting, it helps to look at what it’s being compared against (for example, other anti-androgens and different hormonal combinations), and what cancer stage is involved. The reason can differ for early disease, metastatic hormone-sensitive disease, or castration-resistant prostate cancer.
Sources: I don’t have the specific provided sources needed to cite claims about guideline changes or comparative effectiveness. If you share where you saw “not used now” (a guideline, article, or country), I can tailor the explanation to that context.